This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Henry M. Allen, DO; Rhett L. Jackson; Mark D. Winchester; Larry V. Deck, MD; Michael Allon, MD

Arch Intern Med. 1989;149(5):1123-1126.

Abstract
• Nephrogenic diabetes insipidus (NDI) is a frequent complication in patients receiving long-term lithium therapy. Both thiazide diuretics and amiloride may reduce the polyuria, but the use of each is associated with problems. We report the results of a clinical trial using the nonsteroidal anti-inflammatory drug indomethacin to treat a patient with well-documented lithium-induced NDI that persisted following cessation of lithium treatment. The administration of a single dose of indomethacin resulted in a dramatic decrease in urine volume and increase in urine osmolality that persisted for several hours, and was independent of renal hemodynamic changes. Subsequently, the patient experienced a sustained, favorable effect on her polyuria during long-term (3 months) indomethacin therapy without a deleterious effect on her renal function. Indomethacin may be a useful therapeutic tool for the amelioration of lithium-induced NDI.

(Arch Intern Med. 1989;149:149:1123-1126)

Author Affiliations
From the Department of Medicine, Section of Nephrology, University of Oklahoma School of Medicine, Oklahoma City.

Footnotes
Accepted for publication December 8,1988.

Reprint requests to Section of Nephrology (111G), University of Oklahoma School of Medicine, Veterans Administration Medical Center, 921 NE 13th St, Oklahoma City, OK 73104 (Dr Allon).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus
Zhang et al.
Am. J. Physiol. Renal Physiol. 2009;296:F1194-F1201.
ABSTRACT | FULL TEXT  

Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2
Kim et al.
Am. J. Physiol. Renal Physiol. 2008;294:F702-F709.
ABSTRACT | FULL TEXT  

Treatment of electrolyte disorders in adult patients in the intensive care unit
Kraft et al.
Am J Health Syst Pharm 2005;62:1663-1682.
ABSTRACT | FULL TEXT  

The Management of Diabetes Insipidus in Adults
Singer et al.
Arch Intern Med 1997;157:1293-1301.
ABSTRACT  

Indomethacin in the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
VIERHAPPER
Arch Intern Med 1990;150:2420-2420.
ABSTRACT